| Name | Vernakalant Hydrochloride |
| Description | Vernakalant Hydrochloride (RSD1235 hydrochloride) is a mixed voltage- and frequency-dependent Na+ and atria-preferred K+ channel blocker. |
| In vitro | Block of Kv1.5 by Vernakalant Hydrochloride occurs after channel activation, as Vernakalant induces a rapid block of channel current upon depolarization with minimal resting or “tonic” block. The most significant effect is the reduction in potency at I502A, with an IC50 of 329±19 μM (n=4-10) compared to a control IC50 of 13.4±0.9 μM (n=5-23), reflecting a 25-fold potency decrease. Lesser reductions in potency, between 3- and 4-fold, were noted for V505A, I508A, T480A, and C500A. For wild-type and mutant Kv1.5 channels, IC50 for Vernakalant block are 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channels, Kv1.5 channelI508F, and Kv1.5 channelT479A, respectively [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.18 mM), Sonication is recommended.
DMSO : 45 mg/mL (116.6 mM), Sonication is recommended.
H2O : 45 mg/mL (116.6 mM), Sonication is recommended.
|
| Keywords | Vernakalant Hydrochloride | SodiumChannel | Sodium Channel | RSD-1235 Hydrochloride | RSD1235 Hydrochloride | RSD 1235 Hydrochloride | PotassiumChannel | Potassium Channel | Kv1.5 channelwt | Kv1.5 channel T479A | KV1.5 channel | I508F |
| Inhibitors Related | Minoxidil sulfate | Phenytoin sodium | Hydrochlorothiazide | 1,8-Cineole | Tetraethylammonium bromide | Valproic Acid | L-Aspartic aicd sodium | Ursodeoxycholic acid | Chenodeoxycholic acid | Chlorzoxazone | 2,2,2-Trichloroethanol | Indapamide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
